代谢类疾病,主要包括糖尿病、肥胖症、高血脂、非酒精性脂肪性肝炎(NASH)等,已成为21 世纪全球最严峻的公共卫生挑战之一。随着人口老龄化加剧、生活方式改变以及诊断率提升,全球代谢性疾病患者基数持续扩大,驱动代谢类药物市场进入高速增长通道。预计到2030年,全球代谢类药物市场规模将突破 2000 亿美元,其中 GLP-1 受体激动剂、SGLT-2 抑制剂、多靶点激动剂等创新疗法将成为核心增长引擎。...
Source Link代谢类疾病,主要包括糖尿病、肥胖症、高血脂、非酒精性脂肪性肝炎(NASH)等,已成为21 世纪全球最严峻的公共卫生挑战之一。随着人口老龄化加剧、生活方式改变以及诊断率提升,全球代谢性疾病患者基数持续扩大,驱动代谢类药物市场进入高速增长通道。预计到2030年,全球代谢类药物市场规模将突破 2000 亿美元,其中 GLP-1 受体激动剂、SGLT-2 抑制剂、多靶点激动剂等创新疗法将成为核心增长引擎。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.